Abeona Therapeutics: Funding, Investors & Team (Sep 2026)
Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.
Abeona Therapeutics has raised $173M across 5 funding rounds on record, the most recent an undisclosed round of $75.0M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Abeona Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Abeona Therapeutics Funding Rounds
Abeona Therapeutics raised $17.5M in a Post-IPO Equity announced in Dec 2021.
11 months later, an undisclosed round of $35.0M was announced in Nov 2022.
8 months later, an undisclosed round of $25.0M was announced in Jul 2023.
6 months later, an undisclosed round of $20.0M was announced in Jan 2024.
4 months later, an undisclosed round of $75.0M was announced in May 2024.
Abeona Therapeutics Founders and Leadership Team
Contact details for the Abeona Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Abeona Therapeutics Funding Compared to Other Biotechnology Startups
Abeona Therapeutics' latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Abeona Therapeutics in Biotechnology and New York
Companies Similar to Abeona Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Abeona Therapeutics Funding FAQs
What does Abeona Therapeutics do?
Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.
How much funding has Abeona Therapeutics raised?
Abeona Therapeutics has raised $173M across 5 rounds on record. The most recent is an undisclosed round of $75.0M announced in May 2024.
When did Abeona Therapeutics last raise funding?
Abeona Therapeutics' most recent funding round on record is an undisclosed round of $75.0M, announced in May 2024.
Who founded Abeona Therapeutics?
FundedIQ lists Douglas Mccarty (Founder) at Abeona Therapeutics.
Who is the CEO of Abeona Therapeutics?
Joao Siffert is listed as CEO at Abeona Therapeutics.
Where is Abeona Therapeutics headquartered?
Abeona Therapeutics is based in New York, United States.
How many employees does Abeona Therapeutics have?
Abeona Therapeutics is in the 51-100 employee band.
How does Abeona Therapeutics' funding compare to other Biotechnology startups?
Abeona Therapeutics' latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Abeona Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Abeona Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.